CALIFIA BIO

Over half of all patients with diabetes will eventually develop some form of neuropathy resulting in sensory loss, pain and autonomic dysfunctions which can cause life changing cardiovascular, gastrointestinal, and genitourinary complications. These manifestations of neuropathy reduce a patient’s quality of life. Currently there is no therapy for diabetic neuropathy other than attempts to maintain normal blood glucose levels. Califia Bio, Inc. is part of a research team to investigate the activity of certain kinase inhibitors for the treatment of diabetic neuropathy. The Juvenile Diabetes Research Foundation has awarded a Research Grant (17-2010-795) to a team comprised of Dr. Stephen Dewhurst, Chairman Department of Immunology and Microbiology, University of Rochester Medical Center, Paul Fernyhough, Professor - Departments of Pharmacology and Therapeutics & Physiology, University of Manitoba, and Nigel Calcutt, Professor Pathology, University of California San Diego, and Val Goodfellow, CEO, Califia Bio. Califia Bio has identified several families of kinase inhibitors with the potential to treat peripheral neuropathy. Califia Bio will participate in the optimization of these compounds by testing through in vitro and in vivo models of diabetic neuropathy performed by our academic collaborators. Colin Loweth Ph.D will lead the chemistry efforts at Califia Bio. Califia Bio Inc. is a privately held company based in San Diego, California, and is involved in collaborative research and contract service projects in medicinal chemistry and drug discovery. Contact Val S. Goodfellow, CEO, Califia Bio, Inc.